Premium
P1–140: Soluble BACE activity and sAPPβ levels do not differentiate Alzheimer's disease and age‐matched control cerebrospinal fluid in the ADNI‐1 cohort
Author(s) -
Savage Mary,
Holder Dan,
Wu Guoxin,
Kaplow June M.,
Siuciak Judith,
Potter William
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.362
Subject(s) - cerebrospinal fluid , amyloid precursor protein secretase , apolipoprotein e , alzheimer's disease neuroimaging initiative , amyloid precursor protein , biomarker , medicine , cohort , analysis of variance , disease , gastroenterology , endocrinology , chemistry , pathology , alzheimer's disease , biochemistry
P1-140 SOLUBLE BACE ACTIVITYAND SAPPb LEVELS DO NOT DIFFERENTIATE ALZHEIMER’S DISEASE AND AGE-MATCHED CONTROL CEREBROSPINAL FLUID IN THEADNI-1 COHORT Mary Savage, Dan Holder, Guoxin Wu, June M. Kaplow, Judith Siuciak, William Potter, ADNI 6,7 The Foundation for NIH Biomarkers Consortium CSF Proteomics Project Team, Merck and Company, West Point, Pennsylvania, United States; Merck & Co., West Point, Pennsylvania, United States; Merck Research Laboratories, West Point, Pennsylvania, United States; Eisai Inc., Woodcliff Lake, New Jersey, United States; Foundation for the NIH, Bethesda, Maryland, United States; Foundation for the National Institutes of Health, Bethesda, Maryland, United States; ADNI, ANBDI, District of Columbia, United States; FNIH, Bethesda, Maryland, United States. Contact e-mail: mary_savage@merck. com